BillionToOne
billiontoone.comMore intelligent healthcare for all with single molecule diagnostics.
Health & Wellnessdiagnosticsprenatal-screeningliquid-biopsygenomicsbiotechmolecular-diagnosticscell-free-dna
About
BillionToOne is a molecular diagnostics company developing single-molecule next-generation sequencing (smNGS) technology for prenatal screening and liquid biopsy. Their proprietary Quantitative Counting Templates (QCTs™) platform enables direct measurement of sparse disease-causing DNA fragments from a single blood draw. The company aims to make healthcare more accessible and actionable by advancing early disease detection.
Problem
Current prenatal screening and liquid biopsy methods lack the precision to detect rare, disease-causing DNA variants at the single base-pair level from a simple blood draw.
For
Healthcare providers and patients seeking advanced prenatal screening and liquid biopsy diagnostics
How it works
BillionToOne's proprietary QCTs™ power their smNGS platform to quantify and directly measure sparse disease-causing DNA molecules from cell-free DNA in a blood sample.
Business model
unknown
Status
launched
Company
BillionToOne